Is Zomedica a Buy Under $1?

: ZOM | Zomedica Corp. News, Ratings, and Charts

ZOM – The price of shares of Zomedica (ZOM) skyrocketed earlier this year, driven primarily by investors’ optimism surrounding the pet care industry’s growth. With solid product candidates in its pipeline, ZOM is likely to deliver significant returns in the long term. However, considering the company’s stretched valuations, is the penny stock a buy now? Keep reading to find out.

The veterinary-focused company Zomedica Corp. (ZOM - Get Rating), which is based in Ann Arbor, Mich., develops products for the needs of companion animals. The company is also developing and commercializing its primary product candidate, TRUFORMA, which is a diagnostic biosensor platform for detecting thyroid disorders in dogs and cats and adrenal disorders in dogs.

The stock skyrocketed in price earlier this year, driven by retail investors’ interest, securing its name alongside the other meme stocks that topped the headlines at that time. ZOM traded at around $3.00 during its rally. Furthermore, the stock has gained 455.7% over the past year and 121.7% year-to-date to close its last trading session at $0.51. However, ZOM has slumped 61.3% over the past six months and 10.2% over the past five days.

ZOM’s momentum at the beginning of the year can be attributed mainly to investors’ optimism surrounding the growth of the pet-care industry. Studies show that pet adoption increased substantially during the pandemic last year, leading to an increase in the number of pets being seen by veterinary practices. This led to optimistic growth expectations, attracting retail investors’ attention to the industry.

Investors’ bullish sentiments caused ZOM shares to trade at extremely high valuations. In terms of trailing-12-months EV/Sales, ZOM is currently trading at 7,573.41x compared to the 7.12x industry average. Also, ZOM’s13.11K trailing-12-months Price/Sales ratio is significantly higher than the 7.54 industry average.

Here’s what could shape ZOM’s performance in the near term:

Weak Second-Quarter Financials

For the three months ended June 30, 2021, ZOM’s revenue and gross profit were just $15,693 and negative $20,183, respectively. ZOM reported no revenues or gross profit for the same period last year. Its loss from operations grew marginally from its year-ago value to $5.33 million, while its net loss and comprehensive loss declined 11.3% from the same period last year to $4.71 million. In addition, it’s selling, general and administrative expenses rose 261.3% year-over-year to $5.04 million. Also, its trailing-12-months EPS and EBITDA came in at negative $0.07 and 18.06 million, respectively.

Operational Strategy Shift

ZOM unveiled its plans to expand its direct sales organization earlier this year while phasing out its distributor-based sales efforts. The company expects this transition to provide a stronger foundation to build the marketing and sales of its primary product candidate TRUFORMA® and any future products developed or acquired by ZOM. However, the improvement attributed to this operation switch from a distributor-based sales model to a direct sales organization is expected to take significant time to be reflected in the company’s financials.

POWR Ratings Reflect Bleak Outlook

ZOM has an overall F rating, translating to Strong Sell in our proprietary POWR Ratings system. The POWR Ratings are calculated considering 118 distinct factors, with each factor weighted to an optimal degree.

ZOM has an F grade for Quality. This is consistent with its negative gross profit margin of 39.29% compared with the 54.88% industry average. The company has a Value grade of D, which is in sync with its stretched valuation.

Of the 210 stocks in the F-rated Medical – Pharmaceuticals industry, ZOM is ranked #208.

Beyond what I have stated above, one can also view ZOM’s grades for Momentum, Growth, Sentiment, and Stability here.

View the top-rated stocks in the Medical – Pharmaceuticals industry here.

Bottom Line

With the substantial increase in pet adoption during the pandemic and the stay-at-home mandates, pet care products and veterans were highly demanded. Also, analysts’ projections indicating pet care industry growth attracted investors’ attention to ZOM’s shares.

ZOM benefited significantly from the industry tailwinds at the beginning of the year. However, the upside was short-lived. So, considering the company’s weak bottom line and stretched valuations, ZOM is best avoided now.

How Does Zomedica Corp. (ZOM) Stack Up Against its Peers?

While ZOM has an overall POWR Rating of F, one  might want to consider investing in the following stocks from the same industry with an A (Strong Buy) rating: Novartis (NVS - Get Rating), Johnson & Johnson (JNJ - Get Rating), and GlaxoSmithKline PLC (GSK - Get Rating).

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


ZOM shares were trading at $0.51 per share on Monday afternoon, down $0.01 (-1.15%). Year-to-date, ZOM has gained 121.16%, versus a 17.84% rise in the benchmark S&P 500 index during the same period.


About the Author: Subhasree Kar


Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ZOMGet RatingGet RatingGet Rating
NVSGet RatingGet RatingGet Rating
JNJGet RatingGet RatingGet Rating
GSKGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Investor Alert: Mission Accomplished?

The S&P 500 (SPY) has broken out above the 200 day moving average. Does that mean that bear market fears are now over? And should investors be riding the bull to new heights? Read on for Steve Reitmeister’s answer...

Stock Market Update: It’s Complicated!

The S&P 500 (SPY) may have bounced 17% from recent lows, but the outlook for stocks from here is...in a word...COMPLICATED. Read on to get Steve Reitmeister full market outlook and trading plan for this complicated market environment.

Becoming More Bullish on Stocks, But...

Stocks are on a roll with the S&P 500 (SPY) up more than 10% from the recent lows. Before you start getting too giddy, you should read this updated market outlook and trading plan Steve Reitmeister.

Stock Market Held Hostage

Uncertainty is the term most often applied to this stock market. Uncertainty over tariffs. Uncertainty of whether the S&P 500 (SPY) will fall into bear territory. Uncertainty over what happens next. Steve Reitmeister dives into the uncertainty to make sense of the market in this week’s commentary...

Stock Market Standing on the 50 Yard Line

Steve Reitmeister contemplates where the stock market stands now and what happens next in trying to stay on the right side of the market action. One path points to bear and one to new highs for the S&P 500 (SPY). Which will it be?

Read More Stories

More Zomedica Corp. (ZOM) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ZOM News